Peramivir Miss Drops BioCryst; Catalyst Falls on Cocaine Trial
By Jennifer Boggs
Friday, November 9, 2012
Disappointing clinical data clobbered shares of two biotech firms Thursday: BioCryst Pharmaceuticals Inc. fell 40.4 percent on news that a Phase III trial of influenza candidate peramivir would be halted for futility, while Catalyst Pharmaceutical Partners lost nearly two-thirds of its value after reporting a Phase IIb miss for cocaine-dependence candidate CPP-109.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.